» Articles » PMID: 35686726

Recreational Cannabidiol: Awareness, Prevalence of Use, and Associated Factors in a Representative Sample of the German Population

Overview
Publisher Informa Healthcare
Date 2022 Jun 10
PMID 35686726
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recreational cannabidiol (CBD) is frequently promoted as a medicinal or therapeutic cannabis product worldwide. Nationwide population-based data on awareness and use of recreational CBD are currently lacking.

Objective: This study estimates the prevalence of recreational CBD awareness and use among the population in Germany. It also explores potential associations with socio-demographic characteristics, tobacco smoking, and e-cigarette use.

Methods: We used data from a cross-sectional household survey (German Study on Tobacco Use, DEBRA) fielded across two waves in October-November 2020 and February-March 2021. Data were collected using computer-assisted face-to-face interviews among participants aged ≥14 years (n = 4026). Outcome variables were CBD awareness (yes/no) and CBD ever use (yes/no). The sample was weighted to ensure representativeness of the prevalence estimates. Associations with socio-demographic variables, tobacco smoking, and e-cigarette use were assessed using multivariable logistic regression.

Results: Approximately half of the population in Germany (48.3%, 95% CI: 46.8-49.9) was aware of recreational CBD products, and 4.3% (95% CI: 3.7-5.0) had ever used them (including 1.1% current users). Awareness was associated with younger age, higher education levels, female sex, living in urban regions, no migration background, tobacco smoking, and e-cigarette use. Ever use was associated with higher education levels, living in urban regions, tobacco smoking, and e-cigarette use.

Conclusions: Awareness of recreational CBD products is high but ever use is currently low in Germany. Given the uncertain legal framework regarding the marketing of recreational CBD products, the changing retail landscape, and potential harms of CBD use, structured monitoring is warranted for public health purposes.

Citing Articles

Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims.

Engeli B, Lachenmeier D, Diel P, Guth S, Villar Fernandez M, Roth A Nutrients. 2025; 17(3).

PMID: 39940347 PMC: 11820564. DOI: 10.3390/nu17030489.


Usage and health perception of cannabidiol-containing products among the population in Germany: a descriptive study conducted in 2020 and 2021.

Geppert J, Lietzow J, Hessel-Pras S, Kirsch F, Schafer B, Sachse B BMC Public Health. 2023; 23(1):2318.

PMID: 37996800 PMC: 10666397. DOI: 10.1186/s12889-023-17142-0.


Association of cannabis, cannabidiol and synthetic cannabinoid use with mental health in UK adolescents.

Hotham J, Cannings-John R, Moore L, Hawkins J, Bonell C, Hickman M Br J Psychiatry. 2023; 223(4):478-484.

PMID: 37485911 PMC: 10866672. DOI: 10.1192/bjp.2023.91.


Cannabidiol use and perceptions in France: a national survey.

Casanova C, Ramier C, Fortin D, Carrieri P, Mancini J, Barre T BMC Public Health. 2022; 22(1):1628.

PMID: 36038869 PMC: 9421113. DOI: 10.1186/s12889-022-14057-0.


Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination?.

Lachenmeier D, Habel S, Fischer B, Herbi F, Zerbe Y, Bock V F1000Res. 2024; 8:1394.

PMID: 32117565 PMC: 7029751. DOI: 10.12688/f1000research.19931.7.